← Leaderboards
Y. Alan Wang
University Of Tx Md Anderson Can Ctr
$3,748,710
Attributed
$4,897,074
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,897,074 · 3
By mechanism
R01$4,897,074 · 3
Top collaborators
- Chun Li4 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Heath Devin Skinner$8,539,031
- Lanlan Shen$6,924,000
- Chun Li$8,657,872
- Thomas M Guerrero$3,726,710
- Nancy U Lin$1,025,163
Others in their field
Other Emerging Leaders on “Recruit”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Susan M Landau · University Of California Berkeley$47,252,026
- Prasant Mohapatra · University Of California At Davis$40,097,014
- Scott Andrew Sutherland · Vignet, Inc.$37,105,117
- Mark Begale · Vignet, Inc.$37,105,117
- Neeta Jain · Vignet, Inc.$37,105,117
Research focus
RecruitCellsMouse ModelTumor MicroenvironmentTranscriptome SequencingImmuneUp-RegulationChemoradiationTumorImmune Checkpoint BlockadeEffective TherapySignal TransductionCytometryAntibodiesCytokinePathway InteractionsInfiltrationInhibitorCancer CellMigrationMolecularPhenotypeLoss Of FunctionMutation
Grant awards (12)
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$577,925
R01 · FY2025 · CA
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$552,266
R01 · FY2024 · CA
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM$344,441
R01 · FY2024 · CA · contact PI
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$569,704
R01 · FY2023 · CA
Sex specific epigenetic regulation of colon cancer metastasis$395,576
R01 · FY2023 · CA · contact PI
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma$596,833
R01 · FY2022 · CA
Sex specific epigenetic regulation of colon cancer metastasis$403,649
R01 · FY2022 · CA · contact PI
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM$355,317
R01 · FY2022 · CA · contact PI
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM$3,363
R01 · FY2022 · CA · contact PI
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM$366,000
R01 · FY2021 · CA · contact PI
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM$366,000
R01 · FY2020 · CA · contact PI
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM$366,000
R01 · FY2019 · CA · contact PI